CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) - USD ($) $ in Thousands	Total	Series A convertible preferred stock [Member]	Series A-1 convertible preferred stock [Member]	Series B convertible preferred stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2022		$ 47,458	$ 4,132	$ 59,855
Beginning balance, Shares at Dec. 31, 2022		2,286,873	312,094	2,625,896
Beginning balance, Shares at Dec. 31, 2022					343,550
Beginning balance at Dec. 31, 2022	$ (130,712)				$ 1	$ 2,625	$ (133,338)
Issuance of common stock from option exercises, Shares					16,019
Issuance of common stock from option exercises	106					106
Stock-based compensation expense	1,428					1,428
Other comprehensive loss	0
Net Income (Loss)	(53,743)						(53,743)
Ending balance, Shares at Dec. 31, 2023		2,286,873	312,094	2,625,896
Ending balance at Dec. 31, 2023		$ 47,458	$ 4,132	$ 59,855
Ending balance, Shares at Dec. 31, 2023					359,569
Ending balance at Dec. 31, 2023	(182,921)				$ 1	4,159	(187,081)
Conversion of convertible preferred stock to common stock in connection with the Merge, Share		(2,286,873)	(312,094)	(2,625,896)	5,224,863
Conversion of convertible preferred stock to common stock in connection with the Merger, Value	111,445	$ (47,458)	$ (4,132)	$ (59,855)	$ 1	111,444
Issuance of common stock in the pre-closing financing, Shares					1,682,045
Issuance of common stock in the pre-closing financing, Value	42,000					42,000
Issuance of common stock for conversion of convertible notes, Shares					1,433,410
Issuance of common stock for conversion of Convertible Notes, Value	22,705					22,705
Issuance of common stock to Homology shareholders in reverse recapitalization, Shares					3,229,633
Issuance of common stock to Homology shareholders in reverse recapitalization, Value	64,292					64,292
Reverse recapitalization transaction costs	(10,013)					(10,013)
Issuance of CVR at fair value	$ (180)					(180)
Issuance of common stock from option exercises, Shares	255,486				255,486
Issuance of common stock from option exercises	$ 1,694					1,694
Issuance Of Common Stocks From Rsu Vesting, Shares					12,609
Stock-based compensation expense	4,386					4,386
Other comprehensive loss	0
Net Income (Loss)	(47,733)						(47,733)
Ending balance, Shares at Dec. 31, 2024		0	0	0
Ending balance, Shares at Dec. 31, 2024					12,197,615
Ending balance at Dec. 31, 2024	$ 5,675				$ 2	$ 240,487	$ (234,814)